Novavax jumps 6% on cancer vaccine speculation, but real news is a new royalty model from partner approvals.
Novavax shares rose 6% amid retail trader speculation about its Matrix-M adjuvant being used in cancer vaccines. However, the actual significant development was a quiet announcement last week that its partners received approvals for the 2026-2027 sea...
